Characteristics of lofexidine in pharmacological screening.
Pharmacological and limited toxicological screening tests have been performed in order to provide an initial assessment of a new hypotensive substance, 2-[1-(2,6-dichlorphenoxy)-ethyl-2-imidazoline hydrochloride (lofexidine, Lofetensin and Loxacor). After intravenous and intraduodenal administration, this new delta 2-imidazoline compound caused a dose-related, long-lasting reduction of blood pressure. This effect was demonstrable with doses of only 1-10 microgram/kg (i.v.) and 6-60 microgram/kg (intraduodenally). The results suggest a clonidine-like mechanism of action and provided justification for more detailed pharmacological and toxicological studies.